U.S. regulators are slated to decided by Monday whether to approve Biogen Inc's (BIIB.O) controversial Alzheimer's disease drug, and Wall Street analysts and industry observers are deeply divided on its chances of making it over the finish line.
. And, as a signal of the agency's permissiveness, the decision could have ramifications for other neurological treatments and the broader pharmaceutical industry.
A panel of outside advisers to the FDA voted in November that aducanumab had not been proven to slow Alzheimer's progression, despite a report from agency staff that said results from the successful trial were persuasive. "If the FDA approves aducanumab, could go to circa $400, and if not, to circa $200," Mizuho Securities analyst Salim Syed said in a recent research note.
Others said approval remains possible. "I am going out on a limb, saying a two in three chance or so," ISI Group analyst Umer Raffat said in a recent webcast.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna Applies for Full Approval for Its VaccineModerna has become the latest drug company to apply for full FDA approval for its coronavirus vaccine to use in people 18 or older.
Read more »
FDA Approves New Drug for Yeast InfectionThe tablets are the first new drug approved in the antifungal class in more than 20 years. Few other options have previously been available for the condition.
Read more »
A New (and Expensive) Yeast Infection Treatment Is Coming SoonThe FDA just approved it.
Read more »
Matt Gaetz Buddy Joel Greenberg's Guilty Plea Officially Accepted: What He Admitted ToMatt Gaetz buddy Joel Greenberg's guilty plea was officially accepted today: Here's what the former tax collector admitted to
Read more »
Wall St edges up ahead of key economic data, AMC soarsWall Street's main indexes posted slim gains on Wednesday ahead of key U.S. economic data due later in the week as investors weighed inflation concerns and a fresh surge in so-called 'meme stocks.'
Read more »
Shares of retail favorite AMC nearly double, company woos investors with free popcornShares of retail investor favorite AMC Entertainment Holdings Inc (AMC.N) nearly doubled in price on Wednesday, extending a breathtaking rally and reinvigorating the meme stock phenomenon that has captivated investors.
Read more »